Skip to content

The prospective study on differentiation and treatment of membranous nephropathy by Wenyang Huaji method

The prospective study on differentiation and treatment of membranous nephropathy by Wenyang Huaji method

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000039773
Enrollment
Unknown
Registered
2020-11-08
Start date
2020-12-01
Completion date
Unknown
Last updated
2022-01-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Membranous Nephropathy

Interventions

Sponsors

Beijing Hospital of TCM
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1.Conforms to the MN diagnostic criteria. 2.Conforms to the diagnostic criteria of Shaoyin Taiyin syndrome. 3.The patient has signed the informed consent. 4.Between the ages of 18 and 75. 5.CKD stage I-III, eGFR > 30ml/min, serum albumin > 15g/L.

Exclusion criteria

Exclusion criteria: 1. Progressive membranous nephropathy (progressive decrease of renal function;Kidney biopsy showed necrotizing capillaritis and > 50% large crescent), accompanied by IgA nephropathy, diabetic nephropathy and other kidney diseases. 2. Confirmed by hepatitis B, systemic lupus erythematosus, tumor, drug damage and other factors secondary and need to actively treat the primary disease, such as active hepatitis B and persistent liver function test transaminase abnormalities, or anti-nuclear antibodies, double Abnormal strand DNA, ANCA or other indicators of immune disease. 3. With acute central nervous system disease, severe gastrointestinal disease, a history of HIV infection, a history of mental illness or a history of malignancy. 4. With other organ diseases and dysfunction, and with life-threatening complications such as severely infected persons. 5. Pregnant or lactating women. 6. Other clinical trials are under study.

Design outcomes

Primary

MeasureTime frame
24-hour urine protein;serum albumin;

Secondary

MeasureTime frame
TCM syndrome scores;Anti-PLA2R Antibody;Total Cholesterol;Triglyceride;

Countries

China

Contacts

Public ContactLiu Baoli

Beijing Hospital of TCM

polyliu2000@sina.com+86 18901051212

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026